Corporate Overview
NASDAQ: STTK
May 2, 2024
Forward-Looking Statements
This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on our estimates and assumptions. All statements, other than statements of historical facts included in this presentation, are forward-looking statements, including statements concerning our plans, objectives, goals, strategies, future events, or intentions relating to products and markets; the safety, efficacy and clinical benefits of our product candidates, alone or in combination with other agents; the anticipated timing and design of our planned and ongoing preclinical studies and clinical trials, including initiation of additional cohorts, enrollment, the anticipated timing for data, the association of preclinical data with potential clinical benefit, and the timing of anticipated milestones; plans and objectives of management for future operations and future results of anticipated product development efforts, including with respect to preclinical product candidates; potential benefits of our strategic partnerships; potential addressable market size; our anticipated cash runway; and our liquidity and capital resources and business trends. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this presentation, in addition to those risks and uncertainties, such as the uncertainties inherent in the clinical drug development process, the regulatory approval process, the timing of our regulatory filings, the potential for substantial delays, the risk that earlier study results may not be predictive of future study results, manufacturing risks, and competition from other therapies or products, described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K (File No. 001-39593) for the fiscal year ended December 31, 2023 and elsewhere in such filing and in our other periodic reports and subsequent disclosure documents filed with the U.S. Securities and Exchange Commission.
We cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Forward-looking statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements made in this presentation in the context of these risks and uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. All forward-looking statements in this presentation apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this presentation. We have no intention to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by law.
We obtained the data used throughout this presentation from our own internal estimates and research, as well as from research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released and our own internal research and experience, and are based on assumptions made by us based on such data and our knowledge, which we believe to be reasonable. In addition, while we believe the data included in this presentation is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various factors.
This presentation concerns a discussion of investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.
2
Shattuck Labs
Focused on Improving the Lives of Patients
OUR PURPOSE
Pioneering Novel Therapeutics for Cancer and Autoimmune Diseases
OUR VALUES
Bold, Respectful, Honest, Balanced, Grateful
OUR MISSION
Work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases
OUR VISION
Build incredible medicines off the beaten path by challenging ourselves to think differently
Shattuck Labs Overview
Shattuck Labs (NASDAQ: STTK)
Agonist Redirected Checkpoint (ARC) Platform
ARC Clinical Pipeline Against Validated Oncology Targets
Discovery Platform
Experienced Team and Strong Cash Position
Clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins, with key clinical data from multiple expansion cohorts expected in 2024
- Checkpoint inhibition + costimulatory pathway activation
- High binding affinity and avidity to targets
- Rapid concept to compound to clinic
SL-172154: CD47/SIRPα Inhibitor CD40 Agonist
Multiple Phase 1B clinical trials ongoing in PROC and AML/HR-MDS
- Strategic partnership with Ono Pharmaceutical to develop bifunctional fusion proteins for the treatment of autoimmune and inflammatory diseases
- Highly experienced management team, board of directors, and scientific advisory board
- $114.6 million in cash and cash equivalents and investments as of March 31, 2024
- Cash runway expected to fund operations into 2026
PROC = Platinum-Resistant Ovarian Cancer
4 AML = Acute Myeloid Leukemia
HR-MDS = Higher-Risk Myelodysplastic Syndromes
Shattuck's Clinical-Stage Pipeline
Targeting CD47/SIRPα and CD40 Pathways
Domains | Stage of Development | |||||||||
Platform | Program | Domain 1 | Domain 2 | Indications | Combination | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Agents | ||||||||||
PROC | Liposomal | |||||||||
Doxorubicin | ||||||||||
PROC | Mirvetuximab | |||||||||
Soravtansine | ||||||||||
ARC | SL-172154 | SIRPα | CD40L | |||||||
TP53m AML | Azacitidine |
HR-MDSAzacitidine
TP53wt AML1 | Azacitidine |
+ Venetoclax | |
➔ Developing potential first-in-class CD47 inhibitor in PROC and best-in-class in AML/HR-MDS
1. Potential future cohort, not currently enrolling
5 TP53m = TP53 mutant TP53wt = TP53 wild type
Agonist Redirected Checkpoint (ARC®) Platform
A New Class of Biologic Medicines
6
ARC Platform Technology
Designed to Simultaneously Block Immune Checkpoints and Activate TNF Receptors
6 Checkpoint Binding Domains
Components
Type 1 Extracellular Domains
Fc Domains
Optimized for Target
Type 2 Extracellular Domains
6 TNF Receptor Binding Domains
(Two Sets of TNF Trimers)
Key Advantages
Plug & Play
Modular Technology
12 Binding Domains
High Avidity + Affinity
Hexavalent Binding
2 Distinct Targets
- Tumor necrosis factor, or TNF, receptor superfamily pathways are central to immune cell
function, but effective activation requires trimerization
7
Current Antibody Therapy Approaches Have Limitations
Bivalent Antibodies Cannot Efficiently Activate Trimeric Receptors
A. | B. | C. |
ARC COMPOUND | ||
ANTIBODY | ||
(BIVALENT BINDING) | ||
TNF RECEPTORS | TNF RECEPTOR | 2 SETS OF TRIMERS |
(TRIMER) | (DIMER) |
- CELL
TNF receptors require | Bivalent antibodies cannot bring | ARCs contain two preformed TNF |
trimerization for effective activation, | together TNF receptors to form a | ligand trimers, which match the |
and hexamers signal even more | trimer due to a | requisite structure to efficiently |
effectively than trimers1 | structural mismatch | activate TNF receptor signaling |
8 1. Vanamee E et al. Science Signaling Jan 2018
Highly Experienced Management and Board
Established Track Record of Drug Discovery and Development
Management Team
Taylor Schreiber, MD, PhD | Lini Pandite, MD, MBA | Casi DeYoung, MBA | Andrew R. Neill, MBA | Abhinav Shukla, PhD | George Fromm, PhD | Suresh de Silva, PhD | Stephen Stout, PhD |
Chief Executive Officer | Chief Medical Officer | Chief Business Officer | Chief Financial Officer | Chief Technical Officer | Co-Chief Scientific Officer | Co-Chief Scientific Officer | General Counsel, |
Corporate Secretary and
Chief Ethics and
Compliance Officer
Board of Directors
Helen M. Boudreau | Tyler Brous | Carrie Brownstein, MD | Neil Gibson, PhD | George Golumbeski, PhD | Michael Lee | Taylor Schreiber MD, PhD |
CFO of Proteostasis, | Portfolio Manager, | CMO of Zentalis; VP of | Chief Scientific Officer, | Chairman of the Board; | Redmile Group | Chief Executive Officer, |
FORMA, Novartis US | Lennox Capital Partners, | Global Clinical R&D, | COI Pharma; Chief | EVP of Business | Shattuck | |
LP | Myeloid Diseases, | Scientific Officer, Pfizer | Development, Celgene | |||
Celgen | Oncology |
9 | Note: italicized text denotes prior affiliation |
Focused on Developing Groundbreaking Therapeutics
Addressing Significant Unmet Medical Need
Innovative
Science
Scientific expertise
drives identification of optimized combination of checkpoint inhibition and TNF agonism
Multiple 2024
Catalysts
Phase 1 data readouts
in solid tumors and
hematologic
malignancy programs
(PROC, AML/HR-MDS)
Long-Term Growth
Potential
Potential first-in-class CD47 inhibitor, ARC platform generating
diverse potential
clinical candidates
Financial
Strength
Financial position expected to fund operations into 2026
and multiple inflection
points
10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Shattuck Labs Inc. published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 12:58:20 UTC.